AL Amyloidosis
Clinical research in AL amyloidosis is focused on improving hematologic response in patients who have not achieved an adequate response with previous treatment, with attention to deep response categories such as very good partial response, complete response, and low free light chain burden.
- Isatuximab combinations
- Pomalidomide and dexamethasone
- Free light chain response
The therapeutic interest extends to patients with persistent disease after prior therapy, with an emphasis on response depth and disease control in a plasma cell disorder affecting amyloid-related organ involvement.
Multiple Myeloma
Research in multiple myeloma centers on treatment strategies for newly diagnosed disease, including response-adapted pathways that use minimal residual disease status to guide subsequent therapy and intensification.
- MRD-adapted treatment
- High-dose therapy
- Autologous stem cell transplant
Key areas include the comparison of sequential transplant approaches, consolidation strategies, and post-induction treatment decisions aimed at achieving deeper disease remission.
Immunotherapy and Novel Antibodies
Several trials explore immunotherapy approaches in plasma cell malignancies, with interest in elranatamab as part of both consolidation and maintenance treatment settings.
- Elranatamab
- Lenalidomide
- Standard-of-care comparison
The focus includes antibody-based strategies that may replace or complement conventional treatment in patients requiring ongoing disease suppression.
Deep Response and Disease Monitoring
A recurring theme across the funded studies is the pursuit of deeper remission, with close attention to MRD negativity measured by sensitive molecular methods and to response durability during consolidation and maintenance.
- Next-generation sequencing
- Maintenance therapy
- Progression-free survival
This area reflects a strong therapeutic interest in refining treatment intensity according to residual disease burden and sustaining disease control over time.
